ClinicalTrials.gg
Status unknownNCT03655483Updated Jun 11, 2020

Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma

A Phase 2 interventional study of GLS-010 in Classical Hodgkin's Lymphoma, sponsored by Guangzhou Gloria Biosciences Co., Ltd.. Status unknown at 5 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-06-11.

Sponsored by Guangzhou Gloria Biosciences Co., Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2020), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
85
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 56 studies in Hodgkin Disease with a site in China — 27 open to participants now, 30 under way, 3 of them phase 3. Hodgkin Disease · China.

Planned enrollment
23rd of 53
85 · median 75
Started
2018
with 4 others
Phase 2
26 of 56
13 open now
Registered
15th of 56
by date

Among the 56 studies in Hodgkin Disease with a site in China, this one is the 23rd largest by planned enrollment of the 53 interventional ones that give a count, is one of 5 that started in 2018, is one of 26 in phase 2, and was the 15th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

27 of the 56 studies in Hodgkin Disease with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Hodgkin Disease with a site in China, or all of them as a file.
02

Study summary

Patients with refractory cHL. Patients will be treated with GLS-010

Read the detailed description

Open, uncontrolled, multi-center, phase II study.

03

Conditions studied

  • Classical Hodgkin's Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who met all the criteria below could be selected for the study:

    1. Willingness to participate in the clinical trial. Provide written prior to any study-specific screening procedures. Willingness and capability to comply with the requirements of the study;
    2. Male or female, Age between 18 and 70 years old (margin included) on the day of signing informed consent.
    3. confirmed diagnosis of cHL(classical Hodgkin Lymphoma);
    4. classical Hodgkin Lymphoma patients after 2 or more ( Relapsed cHL patients are defined as patients with new lesion found at primary site or other sites after achieving a complete response after the last treatment; refractory cHL is defined as patients achieve a less than complete response or partial response after the last treatment)and at least one of the following condition is in accordance with:

      1. Participant has failed to achieve a response after treatment with stem cell transplant (auto-SCT) or relapsed after achieving a response.
      2. Participant has failed to achieve a response to, progressed after, or be ineligible for autologous stem cell transplant (auto-SCT)
    5. Based on Lugano 2014, at least one bi-dimensional measurable Lymph node lesion with minimum measurement of > 15 mm or an extranodal lesion with minimum measurement of > 10 mm in the longest diameter of cross-sectional areas in CT test, plus positive on Fluorodeoxyglucose-positron tomography(FDG-PET).
    6. Paraffin embedding sample or sample available during screening;
    7. Must have performance status of 0 or 1
    8. Has a predicted survival period ≥ 12 weeks;
    9. Demonstrate adequate organ and hematopoietic function as defined below:

      1. ≥8.0 g/dL
      2. (ANC) ≥1000 /mcL
      3. ≥75,000 / mcL
      4. Serum total ≤ 1.5 X
      5. (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver
      6. Serum creatinine OR ≤1.5 X upper limit of normal (ULN)
      7. (INR) or Prothrombin Time (PT)≤1.5 X ULN unless subject is receiving anticoagulant therapy, then as long as coagulation parameter (PT /INR or Activated Partial Thromboplastin Time (aPTT) , or anti-Xa factor )is within therapeutic range of intended use of anticoagulants.
    10. Since signing the ICF, female or male subjects of should be willing to use an adequate method of with the spouse for the course of the study through 5 months after the last dose of study medication.

Exclusion criteria

Exclusion Criteria:

  • Subjects who met the following criteria were not eligible for the study:

    1. Nodular lymphocytes is confirmed as primary Hodgkin lymphoma or grey zone lymphoma.
    2. Has known active central nervous system (CNS) .
    3. Has undergone hematopoietic stem cell transplantation.
    4. Has undergone autologous stem cell transplantation within 100 days prior to the first dose of study drug.
    5. Grade 3 or 4 congestive heart failure ( (NYHA)), unstable angina pectoris, poorly controlled arrhythmias(including male ≥ 450 ms, female QTc intervals≥ 470 ms, QTc intervals calculated by Formula Fridericia), acute ischemia on or myocardial infarction within 6 months prior to screening.
    6. Patients with any disease, i.e., but not limited to, interstitial pneumonia, uveitis, enteritis,hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (hypothyroidism without clinical symptoms or caused by radiotherapy and chemotherapy can be included); Patients with vitiligo or asthma CR in Childhood, not requiring any intervention in adulthood are permitted to enroll.; patients with asthma requiring a bronchiectasis intervention are not permitted to enroll.
    7. Subjects that requires systemic (Dose equivalent to or above 10 mg prednisone daily) or other medications;
    8. Has received a live anti-tumor vaccine, or anti-tumor treatment with immunostimulation within 4 weeks prior to pre-screening.
    9. Prior therapy with an , anti-PD-L1, anti-PD-L2, anti-CD137 or anti CTLA-4 antibody (including Ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
    10. Presence of other active cancers within 5 years prior to enrollment. Patients with cervical carcinoma in situ/ cured skin basal cell carcinoma who have received definitive adequate treatment are eligible.
    11. Participants with active viral hepatitis (positive HepB sAg and/or positive HepB core Ab with positive HepB DNA> 103copies/mL, or positive HepC antibody), or syphilis positive.
    12. Has a known (HIV) infection, or other acquired and congenital immune deficiency diseases, or history of organ transplant.
    13. Has history of active TB infection within 1 year prior to enrollment. (Suspected TB infection patient needs chest X-ray, sputum examination and clinical symptom for conformation. Patients with active TB infection should be excluded even if cured.)
    14. Subject that requires systematic treatment for active infection, unexplained fever> 38.5°C prior to the first dose of study drug during screening( Subjects that has tumor related fever could be included while confirmed by the investigator.)
    15. History of allergic reactions attributed to any macromolecular protein preparation/monoclonal antibody, or any other composition of the study drug.
    16. drug therapy outside of this trial during or within 4 weeks prior to GLS-010.
    17. Has had prior chemotherapy, radiation therapy, targeted small molecule therapy or major surgery within 4 weeks prior to the first dose of study drug; who has not recovered (i.e. ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent (alopecia excluded)
    18. Has history of Interstitial Lung Disease or non-infectious pneumonitis (Patients caused by radiotherapy are eligible.)
    19. Has history of alcoholism or drug abuse within 1 year;
    20. Has clear history of neurological or mental disorders, i.e. epilepsy, dementia, and poor compliance.
    21. Has received an anti-infection vaccine within 4 weeks prior to the first dose of study drug (i.e. Influenza virus vaccines, HPV vaccines). Any are not allowed during the study.
    22. Pregnancy or lactation.
    23. Other conditions that do not permit compliance with the protocol, evaluated by the investigator.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
85 participants (estimated)

Study arms

  • Experimental
    GLS-010

    GLS-010

    Drug: GLS-010

Interventions

  • Full-human anti-pd-1 monoclonal antibodies

    Also known as: Full-human anti-pd-1 monoclonal antibodies

06

What researchers measure

Primary outcomes

  1. Objective response rate

    Based on an independent image assessment board

    Time frame: 2 months

Secondary outcomes

  1. PFS

    meaningful benefit in PFS based on Lugano 2014

    Time frame: 8 weeks

  2. OS

    Overall survival

    Time frame: within 3 years of last patient enrolled

  3. DCR

    meaningful benefit in DCR based on Lugano 2014

    Time frame: 8 weeks

  4. DOR

    meaningful benefit in DOR based on Lugano 2014

    Time frame: 8 weeks

  5. TTR

    meaningful benefit in TTR based on Lugano 2014

    Time frame: 8 weeks

07

Study locations

5 sites
  • Guizhou Cancer Hospital
    Guiyang, Guizhou, China
  • Hunan Cancer Hospital
    Changsha, Hunan, China
  • Sichuan Cancer Hospital
    Chengdu, Sichuan, China
  • Tianjin Cancer Hospital
    Tianjin, Tianjin, China
  • Peking University Cancer Hospital & Institute
    Beijing, China
08

References and documents

Publications

  • Lin N, Zhang M, Bai H, Liu H, Cui J, Ke X, Zhang H, Liu L, Yan D, Jiang Y, Zang A, Qi J, Wang L, Liu Z, Xu B, Zhang Y, Zhang Z, Zhao X, Hu C, Yang S, Zhou H, Shi J, Shao Z, Xiang Y, Zhu J, Song Y, Zhu J. Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study. Eur J Cancer. 2022 Mar;164:117-126. doi: 10.1016/j.ejca.2021.07.021. Epub 2021 Aug 27. PubMed 34462189 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2018 (actual). Primary completion is estimated for Apr 2021, 31 months after the start.

Of 206 phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 111. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2018
First posted
Aug 31, 2018
StartActual
Aug 24, 2018
Primary completionEst.
Apr 11, 2021
CompletionEst.
Apr 11, 2022
Last update
Jun 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03655483
Lead sponsor
Guangzhou Gloria Biosciences Co., Ltd.
Responsible party
Sponsor
First posted
Aug 31, 2018
Start date
Aug 24, 2018
Primary completion
Apr 11, 2021 (estimated)
Completion
Apr 11, 2022 (estimated)
Last update
Jun 11, 2020

Study contacts

Jun Zhu, MD
principal investigator · Peking University Cancer Hospital & Institute
Yuqin Song, MD
principal investigator · Peking University Cancer Hospital & Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zimberelimab

Start the discussion